In 2021, for the first time, sales of the little blue pill that treats sexual dysfunction were surpassed by those of the little yellow pill for corporate dysfunction.
“As a society we’ve finally gotten to the point where we’re not ashamed to admit we may need a little help performing at work,” says Dr. Leo LaDuke of Spokane’s Palmeri Insititute.
The yellow pill first hit the market in 2012, when just 17 were sold. It has since proven effective in battling conditions like pulminary volcose (the inability to hit the ground running), generic hyperlation (weak consensus building skills) and Malltin’s Phenomonen (which prevents the brain from processing vision statements).
By 2023, the pill will also help reduce the effects of hyper pinguination (freezing up while brainstorming) and balance festicia (tripping while walking a fine line).
Sales of the yellow pill were only slightly higher last year – 23,000,500,000 to 23,000,500,024 – but they’re expected to grow 400-fold over the next two years. Blue pill sales, meanwhile, are expected to decline.
“Being good at sex may be considered a good thing,” says Dr. LaDuke, “but it’s becoming increasingly apparent that being good at work is considered even better.”
